In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
La haute juridiction a examiné, vendredi 17 avril, un recours déposé notamment par l’association Anticor contre le décret du 11 février nommant l’ancienne ministre de l’action et des comptes à la tête ...
Recent transactionsRecursion Pharmaceuticals insiders reported 5 transactions totaling $366,367.08. Activity included 2 stock sales and 1 tax payment, with the remaining 2 transactions valued at $0.
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results